A bibliometric analysis of the impact of COVID-19 vaccines on the immune system (2020-2024)
Keywords:
COVID-19 vaccines, immune system, bibliometric analysis, vaccine-induced immunity, global research trends, vaccination strategies.Abstract
Background and aim: The rapid development and deployment of COVID-19 vaccines have been pivotal in mitigating the global pandemic, yet the long-term impact of these vaccines on the immune system remains an area of ongoing investigation.
Methods: This bibliometric analysis aims to provide a comprehensive evaluation of global research trends and key findings related to the effects of COVID-19 vaccines on immune function, drawing on data from the Scopus and Web of Science Core Collection (WOS-CC) databases. Data merging, statistical analyses, and visualizations were conducted using RStudio and the Bibliometrix R package.
Results: We analyzed 377 research and review articles published between 2020 and 2024, identifying trends in publication volume, citation metrics, and keyword frequency. Our findings highlight the complexity of vaccine-induced immunity, including the durability of immune responses, interactions with other vaccines, and potential alterations in immune surveillance. The analysis also underscores the importance of collaborative research efforts, with significant contributions from leading institutions and countries.
Conclusions: This study offers valuable insights into the evolving landscape of COVID-19 vaccine research, emphasizing the need for continued investigation to optimize vaccination strategies and address emerging public health challenges.
References
1. Marcassoli A, Leonardi M, Passavanti M, et al. Lessons learned from the lessons learned in public health during the first years of COVID-19 pandemic. Int J Environ Res Public Health. 2023;20(3):1785. doi: 10.3390/ijerph20031785
2. Inchingolo AD, Malcangi G, Ceci S, et al. Effectiveness of SARS-CoV-2 vaccines for short- and long-term immunity: a general overview for the pandemic contrast. Int J Mol Sci. 2022;23(15):8485. doi: 10.3390/ijms23158485
3. Pennisi F, Genovese C, Gianfredi V. Lessons from the COVID-19 pandemic: promoting vaccination and public health resilience, a narrative review. Vaccines. 2024;12(8):891. doi: 10.3390/vaccines12080891
4. Mahil SK, Bechman K, Raharja A, et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 2021;3(9):e627–37. doi: 10.1016/S2665-9913(21)00212-5
5. Huang L, Lai FTT, Yan VKC, et al. Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic. NPJ Vaccines. 2022;7(1):162. doi: 10.1038/s41541-022-00594-7
6. Kow CS, Hasan SS. Potential interactions between COVID-19 vaccines and antiepileptic drugs. Seizure. 2021;86:80–1. doi: 10.1016/j.seizure.2021.01.021
7. Mohammed I, Nauman A, Paul P, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother . 2022;18(1):2027160. doi: 10.1080/21645515.2022.2027160
8. Boccellino M. COVID-19 pandemic: therapeutic strategies and vaccines. Int J Mol Sci. 2023;25(1):556. doi: 10.3390/ijms25010556
9. Arunachalam PS, Lai L, Samaha H, et al. Durability of immune responses to mRNA booster vaccination against COVID-19. J Clin Invest. 2023;133(10):e167955. doi: 10.1172/JCI167955
10. Badary OA. Implications of potential clinically relevant interactions between COVID‐19 vaccines and concomitant medications. Rev Med Virol. 2023;33(3):e2417. doi: 10.1002/rmv.2417
11. Morlanes Pallás R. Innate and adaptative immune mechanisms of COVID-19 vaccines. Serious adverse events associated with SARS-CoV-2 vaccination: A systematic review. Vacunas. 2024;25(2):285.e1-285.e94. doi: 10.1016/j.vacune.2024.05.002
12. Khandker SS, Godman B, Jawad MdI, et al. A systematic review on COVID-19 vaccine strategies, their effectiveness, and issues. Vaccines. 2021;9(12):1387. doi: 10.3390/vaccines9121387
13. Khalid K, Poh CL. The promising potential of reverse vaccinology-based next-generation vaccine development over conventional vaccines against antibiotic-resistant bacteria. Vaccines. 2023;11(7):1264. doi: 10.3390/vaccines11071264
14. Montazeri AS, Zare A, Aghdam NF,et al Ethical challenges for patients and healthcare providers with the approach to COVID-19 context: a review. West Kazakhstan Med J. 2024;66(1):16–29. doi: 10.18502/wkmj.v66i1.15600
15. Zabidi NZ, Liew HL, Farouk IA, et al. Evolution of SARS-CoV-2 variants: implications on immune escape, vaccination, therapeutic and diagnostic strategies. Viruses. 2023;15(4):944. doi: 10.3390/v15040944
16. Baspakova A, Bazargaliyev YSh, Kaliyev AA, et al. Bibliometric analysis of the impact of ultra‐processed foods on the gut microbiota. Int J of Food Sci Tech. 2024;59(3):1456–65. doi: 10.1111/ijfs.16894
17. Wu Y, Wang F, Shen C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274–8. doi: 10.1126/science.abc2241
18. Carreño JM, Alshammary H, Tcheou J, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2022;602(7898):682–8. doi: 10.1038/s41586-022-04399-5
19. Venable GT, Shepherd BA, Loftis CM, et al. Bradford’s law: identification of the core journals for neurosurgery and its subspecialties. J Neurosurg. 2016;124(2):569–79. doi: 10.3171/2015.3.JNS15149
20. Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020;11(1):2806. doi: 10.1038/s41467-020-16638-2
21. Vanderheiden A, Ralfs P, Chirkova T, et al. Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J Virol. 2020;94(19):e00985-20. doi: 10.1128/JVI.00985-20
22. Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine. J Clin Invest. 2021;131(13):e150319. doi: 10.1172/JCI150319
23. Toyoshima Y, Nemoto K, Matsumoto S, et al. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. 2020;65(12):1075–82. doi: 10.1038/s10038-020-0808-9
24. Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cell Signal. 2020;74:109721. doi: 10.1016/j.cellsig.2020.109721
25. Spencer AJ, McKay PF, Belij-Rammerstorfer S, et al. Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. Nat Commun. 2021;12(1):2893. doi: 10.1038/s41467-021-23173-1
26. Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun. 2020;3:100051. doi: 10.1016/j.jtauto.2020.100051
27. Lederer K, Bettini E, Parvathaneni K, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022;185(6):1008-1024.e15. doi: 10.1016/j.cell.2022.01.027
28. Khaddage-Soboh N, Tawil S. Navigating the crisis: A review of COVID-19 research and the importance of academic publications - The case of a private university in Lebanon. Heliyon. 2023;9(12):e22917. doi: 10.1016/j.heliyon.2023.e22917
29. Böröcz K, Kinyó Á, Simon D, Erdő-Bonyár S, et al. Complexity of the immune response elicited by different COVID-19 vaccines, in the light of natural autoantibodies and immunomodulatory therapies. Int J Mol Sci. 2023;24(7):6439. doi: 10.3390/ijms24076439
30. Abufares HI, Oyoun Alsoud L, Alqudah MAY, et al. COVID-19 Vaccines, Effectiveness, and Immune Responses. Int J Mol Sci. 2022;23(23):15415. doi: 10.3390/ijms232315415
31. Okoeguale J, Okobi OE, Ojukwu EC, et al. Maternal seroprevalence and placental transfer of covid-19 antibodies in pregnancy: a hospital-based study. Cureus. 2023;15(11):e49730. doi: 10.7759/cureus.49730
32. Trougakos IP, Terpos E, Alexopoulos H, et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med. 2022;28(7):542–54. doi: 10.1016/j.molmed.2022.04.007
33. Elliott T, Cheeseman HM, Evans AB, et al. Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines. PLoS Pathog. 2022;18(10):e1010885. doi: 10.1371/journal.ppat.1010885
34. Jit M, Ananthakrishnan A, McKee M, et al. Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. Lancet Reg Health Eur. 2021;9:100221. doi: 10.1016/j.lanepe.2021.100221
35. Mohamed K, Rzymski P, Islam MS, et al. COVID‐19 vaccinations: The unknowns, challenges, and hopes. J Med Virol. 2022;94(4):1336–49. doi: 10.1002/jmv.27487
36. El-Menyar A, Khan NA, Mekkodathil A, et al. A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time? Medicine. 2022;101(37):e30609. doi: 10.1097/MD.0000000000030609
37. Ao D, He X, Liu J, et al. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Sig Transduct Target Ther. 2023;8(1):466. doi: 10.1038/s41392-023-01724-w
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.